GlobeNewsWire
31 May 2026, 23:30 UTC · 16w ago
Verdict
Headline takes no side. We score AAPG +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Phase Ib study results for olverembatinib combined with blinatumomab showed encouraging clinical activity and strong response rates in patients with relapsed/refractory Ph+ BCP-ALL or CML-LBP.
So whatPositive clinical data in difficult-to-treat cancer indications typically drives significant upward valuation for biotech firms.
More positive than 92% of claims this week
Ascentage Pharma is conducting three global registrational Phase III studies for olverembatinib, with two cleared by the FDA and EMA.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 85% of claims this week
Takeda holds an exclusive option agreement to license the global rights for olverembatinib outside of Greater China.
So whatA potential partnership with a major pharmaceutical company like Takeda provides a significant non-dilutive funding path and commercial validation.
More positive than 76% of claims this week
The combination therapy was reported as generally well tolerated with a safety profile consistent with individual agent toxicities.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company presented encouraging Phase Ib clinical data and rapid oral presentations at the ASCO 2026 meeting for its core product olverembatinib.
More positive than 46% of ticker scores this week
Takeda holds an exclusive option agreement to license and commercialize olverembatinib globally outside of Greater China.
More positive than 46% of ticker scores this week
Innovent Biologics is jointly commercializing olverembatinib in China, benefiting from the drug's approvals and positive clinical data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
4d ago
−24.7%
Price is moving against the score
$15.06 vs $20.01 close before publication (May 29) · not market-adjusted
AAPG chart →
